EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis.

BMC Cancer · 2024 · PMC11555867 · PMID 39533233

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

showed a trendno p-value reported

Lazertinib plus amivantamab (HR 0.78, 95% CI 0.59 to 1.03) showed a trend towards more prolonged progression-free survival compared to osimertinib alone, though this difference did not reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.